Table 3.
Whole group pathology outcomes of systematic biopsy and targeted biopsy.
| Targeted biopsy | Systematic biopsy | Total | ||
|---|---|---|---|---|
| No cancer | ≤2 cores Gleason 6 | ≥3 cores Gleason 6 or ≥Gleason 7 | ||
| Not performed | 15 | 6 | 3 | 24 |
| No cancer | 22 | 3 | 4 | 29 |
| ≤2 cores Gleason 6 | 2 | 4 | 4 | 10 |
| ≥3 cores Gleason 6 or ≥Gleason 7 | 3 | 0 | 16 | 19 |
| Total | 42 | 13 | 27 | 82 |
Pathology outcomes per patient for systematic biopsy and targeted MR/US fusion biopsy. The numbers in bold indicate patients with a pathology upgrade of clinical importance with systematic biopsy. The numbers in italics indicate patients with a pathology upgrade of clinical importance with targeted biopsy.